Overview

Investigation on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NN9924 in Healthy Male Subjects

Status:
Completed
Trial end date:
2011-07-01
Target enrollment:
Participant gender:
Summary
This trial is conducted in Europe. The aim of the trial is to investigate safety, tolerability, pharmacokinetics (the rate at which the body eliminates the trial drug) and pharmacodynamics (the effect of the investigated drug on the body) of NN9924 in healthy male subjects
Phase:
Phase 1
Details
Lead Sponsor:
Novo Nordisk A/S